A5068874466- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Head and Neck Surgical Oncology
- Gastric Cancer Management and Outcomes
- Cancer-related molecular mechanisms research
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cervical Cancer and HPV Research
- Advanced Radiotherapy Techniques
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Breast Cancer Treatment Studies
- Renal cell carcinoma treatment
University of Hong Kong
2016-2025
Dongnam Institute of Radiological & Medical Sciences
2024
Chinese University of Hong Kong
2004-2024
Laboratory of Data Discovery for Health
2023
Queen Mary Hospital
1995-2021
University of Hong Kong - Shenzhen Hospital
2017-2018
Taiho Pharmaceutical (Japan)
2018
Sanofi (Mexico)
2018
Bayer (United States)
2018
Amgen (United States)
2018
Current practice of adding concurrent–adjuvant chemotherapy to radiotherapy (CRT) for treating advanced nasopharyngeal carcinoma is based on the Intergroup-0099 Study published in 1998. However, outcome radiotherapy-alone (RT) group that trial was substantially poorer than those other trials, and there were no data late toxicities. Verification long-term therapeutic index this regimen needed. Patients with nonkeratinizing staged T1-4N2-3M0 randomly assigned RT (176 patients) or CRT (172...
An accurate staging system is crucial for cancer management. Evaluations continual suitability and improvement are needed as treatment methods evolve.This was a retrospective study of 1609 patients with nasopharyngeal carcinoma investigated by magnetic resonance imaging, staged the 7th edition American Joint Committee on Cancer (AJCC)/International Union Against (UICC) system, irradiated intensity-modulated radiotherapy at 2 centers in Hong Kong mainland China.Among without other T3/T4...
BACKGROUND A current recommendation for locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy with concurrent cisplatin plus adjuvant and fluorouracil (PF). In this randomized trial, the authors evaluated potential therapeutic benefit from changing to an induction‐concurrent chemotherapy sequence, replacing oral capecitabine, and/or using accelerated rather than fractionation. METHODS Patients stage III through IVB, nonkeratinizing NPC were randomly...
BACKGROUND The objective of this study was to develop a nomogram for refining prognostication patients with nondisseminated nasopharyngeal cancer (NPC) staged the proposed 8th edition American Joint Committee on Cancer (AJCC)/Union International Control (UICC) staging system. METHODS Consecutive who had been investigated magnetic resonance imaging, AJCC/UICC system, and irradiated intensity‐modulated radiotherapy from June 2005 December 2010 were analyzed. A cohort 1197 treated at Fujian...
The eighth edition of the American Joint Committee on Cancer (AJCC)/Union for International Control (UICC) stage classification (TNM) nasopharyngeal carcinoma (NPC) was launched. It remains unknown if incorporation nonanatomic factors into would better predict survival. We prospectively recruited 518 patients with nonmetastatic NPC treated radical intensity-modulated radiation therapy ± chemotherapy based TNM. Recursive partitioning analysis (RPA) incorporating pretreatment plasma...
Importance Whether stereotactic body radiotherapy (SBRT) as a bridge to liver transplant for hepatocellular carcinoma (HCC) is effective and safe still unknown. Objective To investigate the feasibility of SBRT before deceased donor (DDLT) previously untreated unresectable HCC. Design, Setting, Participants In this phase 2 nonrandomized controlled trial conducted between June 1, 2015, October 18, 2019, 32 eligible patients within UCSF (University California, San Francisco) criteria underwent...
BACKGROUND Concurrent‐adjuvant chemoradiotherapy (CRT) became a recommended treatment for locoregionally advanced nasopharyngeal carcinoma (NPC) with the first report of significant survival benefit from Intergroup 0099 study. However, data on late toxicities are lacking. Previous reports current NPC‐9901 trial have raised concerns about failure to improve overall (OS) because an inadequate impact distant control and increases in toxicities/noncancer deaths. Validation long‐term therapeutic...
We hypothesized that radiation-induced lymphopenia could be predicted by the effective dose to circulating immune cells (EDIC) in advanced esophageal squamous cell carcinoma treated with trimodality therapy according Dutch ChemoRadiotherapy for Oesophageal cancer followed Surgery Study (CROSS) trial regimen. To test this hypothesis, we examined effect of EDIC on degree lymphocyte drop (lymphocyte nadir).Patients nonmetastatic a single tertiary center from 2012 2018 were eligible study. All...
// Victor Ho-Fun Lee 1 , Dora Lai-Wan Kwong To-Wai Leung Cheuk-Wai Choi Vincent Lai 2 Lydia Ng 3 Ka-On Lam Sherry Chor-Yi Chun-Kin Sze Chi-Chung Tong Patty Pui-Ying Ho Wing-Lok Chan Lai-San Wong Dennis Kwok-Chuen Sum-Yin Pek-Lan Khong Department of Clinical Oncology, Queen Mary Hospital, Li Ka Shing Faculty Medicine, The University Hong Kong, Kong Diagnostic Radiology, Radiation Southern California, Los Angeles, USA Correspondence to: Lee, email: vhflee@hku.hk Keywords: intensity-modulated...
A current recommendation for the treatment of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy (RT) concurrent cisplatin followed by adjuvant and 5-fluorouracil (PF). This randomized NPC-0501 trial evaluated therapeutic effect changing to an induction-concurrent sequence or accelerated-fractionation sequence, and/or replacing capecitabine (X).Patients American Joint Committee on Cancer/International Union Against Cancer stage III...
<h3>Importance</h3> Immune checkpoint inhibitors have been approved for use as a second-line therapy hepatocellular carcinoma (HCC) in patients who previously received sorafenib. Pembrolizumab has shown substantial antitumor activity and favorable toxicity profile treatment of HCC. However, considering the high cost pembrolizumab, there is need to assess its value by both clinical efficacy cost. <h3>Objective</h3> To evaluate cost-effectiveness pembrolizumab vs placebo with HCC from US payer...
Chemotherapy, when added to radiotherapy, improves survival in locally advanced nasopharyngeal carcinoma (NPC). This article presents the second update of Meta-Analysis Chemotherapy NPC.Published or unpublished randomized trials assessing radiotherapy (±a chemotherapy timing) with/without non-metastatic NPC patients were identified. Updated data sought for studies included previous rounds meta-analysis. The primary endpoint was overall survival. All analyzed following intent-to-treat...
Background: The IMbrave 150 trial revealed that atezolizumab plus bevacizumab (atezo–bev) improves survival in patients with unresectable hepatocellular carcinoma (HCC) (1 year rate: 67.2% vs. 54.6%). We assessed the cost-effectiveness of atezo–bev sorafenib as first-line therapy HCC from US payer perspective. Methods: Using data 150, we developed a Markov model to compare lifetime cost and efficacy systemic those sorafenib. main outcomes were life-years, quality-adjusted life-years (QALYs),...